Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Secret_Agent_Man who wrote (813)	5/6/1998 7:17:00 PM
From: Sam Citron	Read Replies (1) \| Respond to of 2135

All we need now is a "Race to the Bottom" worldwide competition in laxity of pharmaceutical regulation. Perhaps an off-shore bio export zone, analogous to Malaysia and Taiwan chippie initiatives, but geared instead to human cloning and quickie clinical trials. Maybe get some IDB export promotion assistance. It staggers the imagination...

To: Secret_Agent_Man who wrote (813)	5/6/1998 7:52:00 PM
From: seminole	Read Replies (1) \| Respond to of 2135

Byron Their is too much talk of shrinking tumors in mice and not enough talk about the variety and aggressiveness of the tumors used in the mouse model in this testing. In short, has the drug been tested on aggressive human tumors capable of metastases and multidrug resistance or something that makes their data look good. This is not an attack on your drug or stock but a warning to be careful out there. As an investors you need to focus on the tumor type not the number of tumors that shrink. Wishing I had a dollar for every mouse tumor my drug shrank richard